Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more
Aclaris Therapeutics Inc (ACRS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.091x
Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has a cash flow conversion efficiency ratio of -0.091x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.93 Million) by net assets ($120.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aclaris Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aclaris Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aclaris Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Saixiang Technology Co Ltd
SHE:002337
|
0.025x |
|
Cerus Corporation
NASDAQ:CERS
|
0.095x |
|
Xi'an High Voltage Apparatus Research Institute Co. Ltd.
SHG:688334
|
N/A |
|
Hyosung Advanced Materials Corp
KO:298050
|
0.044x |
|
CIR S.p.A. - Compagnie Industriali Riunite
F:BN7
|
0.045x |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
0.061x |
|
Beijing Strong Biotechnologies Inc
SHE:300406
|
0.046x |
|
Jiangsu Rutong Petro-Machinery
SHG:603036
|
0.044x |
Annual Cash Flow Conversion Efficiency for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Aclaris Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $155.55 Million | $-20.07 Million | -0.129x | +74.10% |
| 2023-12-31 | $157.18 Million | $-78.33 Million | -0.498x | -45.75% |
| 2022-12-31 | $197.62 Million | $-67.57 Million | -0.342x | -29.42% |
| 2021-12-31 | $197.34 Million | $-52.13 Million | -0.264x | +74.25% |
| 2020-12-31 | $37.65 Million | $-38.63 Million | -1.026x | +25.62% |
| 2019-12-31 | $69.91 Million | $-96.44 Million | -1.380x | -194.38% |
| 2018-12-31 | $215.12 Million | $-100.81 Million | -0.469x | -93.11% |
| 2017-12-31 | $225.26 Million | $-54.66 Million | -0.243x | -18.86% |
| 2016-12-31 | $169.49 Million | $-34.60 Million | -0.204x | +7.27% |
| 2015-12-31 | $92.52 Million | $-20.37 Million | -0.220x | -159.84% |
| 2014-12-31 | $-20.75 Million | $-7.64 Million | 0.368x | -31.48% |
| 2013-12-31 | $-9.16 Million | $-4.92 Million | 0.537x | -- |